Cordicity initially focuses on atrial fibrillation and valvular heart disease, two areas where their technology can provide rapid and significant patient benefit. The software provides physicians with valuable information about heart function, facilitating risk assessment, treatment planning, and surgical procedures. It can also help assess the impact of medications and be used for educational purposes.
“Cordicity is addressing a large and important medical problem, and the market has already shown interest in their innovative software. Their strong research background and unique team make them particularly promising,” says Stefan Asplund, Investment Manager at LiU Invest.
Linus Ohlsson, CEO of Cordicity, views the investment as a crucial step in the company’s development:
“We are incredibly pleased to have LiU Invest as a partner on our journey. They possess the right expertise and experience to support us in this phase, especially with their knowledge in research-based startups. Even during the investment process, they have been a valuable sounding board, and we look forward to their support in upcoming funding rounds and business development.”
